Finance entity
earnings is the sole category represented across all 1 tracked stories. ADC Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. ADC Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.3. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window. We currently track 1 Finance story that mention Tenax Therapeutics, all published on March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 88 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tenax Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics released their full-year 2025 financial results, highlighting critical pipeline milestones and cash runway extensions. The reports underscore a pivotal shift toward Phase 3 data readouts and commercial scaling in the specialized biotech sector.
Tenax Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
